← Leaderboards
Ratna B Ray
Saint Louis University
$12,129,779
Attributed
$12,981,966
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,981,966 · 10
By mechanism
R01$11,019,047 · 5
R21$1,668,919 · 4
R56$294,000 · 1
Top collaborators
- Ranjit Ray5 shared
Most similar at Saint Louis University
Same institution · by research overlap
- John E Tavis$13,372,324
- Xiaofeng Fan$2,745,313
- Elizabeth A Baker$17,335,941
Others in their field
Top investigators on “Growth”
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$233,131,631
- Albert Lazzarini · California Institute Of Technology$170,110,000
- David H Reitze · University Of Florida$170,110,000
- Garret A Fitzgerald · University Of Pennsylvania$153,184,124
- David Heimbrook · Leidos Biomedical Research, Inc.$143,966,408
- Carol Nesel · Westat$116,355,411
Research focus
GrowthBaseHepatitis CMediatingHepatitis C VirusPublic Health RelevanceTreatment StrategyHepatocyteFutureMolecularAnimal ModelMalignant NeoplasmsSignal PathwayChronic Hepatitis CIn VitroPrimary Carcinoma Of The Liver CellsDisease ProgressionAntiviral AgentsCellsModalityEffective TherapyPreventiveGenesVirus
Grant awards (45)
Developing new therapeutic strategies against head and neck cancer$480,690
R01 · FY2025 · DE · contact PI
Developing new therapeutic strategies against head and neck cancer$471,077
R01 · FY2024 · DE · contact PI
Developing new therapeutic strategies against head and neck cancer$483,667
R01 · FY2023 · DE · contact PI
Developing new therapeutic strategies against head and neck cancer$436,022
R01 · FY2022 · DE · contact PI
Hepatitis C virus infection and mechanism of liver disease progression$340,875
R01 · FY2021 · DK
Hepatitis C virus infection and mechanism of liver disease progression$340,875
R01 · FY2020 · DK
HCV infection, cross-talk among liver cells, and liver disease progression$340,875
R01 · FY2020 · DK · contact PI
Mechanistic Insights of BME mediated inhibition of head and neck cancer growth$378,750
R01 · FY2019 · DE · contact PI
HCV infection, cross-talk among liver cells, and liver disease progression$340,875
R01 · FY2019 · DK · contact PI
Hepatitis C virus infection and mechanism of liver disease progression$340,875
R01 · FY2019 · DK
Mechanistic Insights of BME mediated inhibition of head and neck cancer growth$378,750
R01 · FY2018 · DE · contact PI
HCV infection, cross-talk among liver cells, and liver disease progression$340,875
R01 · FY2018 · DK · contact PI
Hepatitis C virus infection and mechanism of liver disease progression$340,875
R01 · FY2018 · DK
Mechanistic Insights of BME mediated inhibition of head and neck cancer growth$378,750
R01 · FY2017 · DE · contact PI
Hepatitis C virus infection and mechanism of liver disease progression$340,875
R01 · FY2017 · DK
HCV infection, cross-talk among liver cells, and liver disease progression$340,875
R01 · FY2017 · DK · contact PI
Mechanistic Insights of BME mediated inhibition of head and neck cancer growth$378,750
R01 · FY2016 · DE · contact PI
HCV infection, cross-talk among liver cells, and liver disease progression$340,875
R01 · FY2016 · DK · contact PI
Establishment of PDX mouse models and cell lines from hepatitis C virus associated liver cancer patients from CA and AA ethnic groups$199,954
R21 · FY2016 · CA · contact PI
Racial Disparity of microRNA in Hepatitis C Virus Mediated Hepatocellularcarcinoma$177,066
R21 · FY2016 · CA · contact PI
Breast Cancer Prevention Using Bitter Melon as a Natural Product$164,756
R21 · FY2016 · CA · contact PI
Mechanistic Insights of BME mediated inhibition of head and neck cancer growth$378,750
R01 · FY2015 · DE · contact PI
Racial Disparity of microRNA in Hepatitis C Virus Mediated Hepatocellularcarcinoma$212,479
R21 · FY2015 · CA · contact PI
Breast Cancer Prevention Using Bitter Melon as a Natural Product$197,708
R21 · FY2015 · CA · contact PI
Innate Immunity and Hepatitis C Virus Infection$303,424
R01 · FY2013 · DK · contact PI
Innate Immunity and Hepatitis C Virus Infection$314,429
R01 · FY2012 · DK · contact PI
Innate Immunity and Hepatitis C Virus Infection$314,429
R01 · FY2011 · DK · contact PI
Bitter melon and chemoprevention of prostate cancer$155,594
R21 · FY2011 · CA · contact PI
Innate Immunity and Hepatitis C Virus Infection$350,460
R01 · FY2010 · DK · contact PI
Bitter melon and chemoprevention of prostate cancer$192,488
R21 · FY2010 · CA · contact PI
Innate Immunity and Hepatitis C Virus Infection$354,000
R01 · FY2009 · DK · contact PI
Developing an in vitro system for HCV propagation$152,613
R21 · FY2009 · AI · contact PI
Developing an in vitro system for HCV propagation$33,126
R21 · FY2009 · AI · contact PI
Developing an in vitro system for HCV propagation$183,135
R21 · FY2008 · AI · contact PI
FUNCTIONAL ROLE OF MBP 1$113,267
R01 · FY2006 · CA · contact PI
HCV NS5A protein and pathogenesis$294,000
R56 · FY2005 · AI
FUNCTIONAL ROLE OF MBP 1$167,327
R01 · FY2005 · CA
HEPATITIS C VIRUS NS5A PROTEIN AND PATHOGENESIS$250,054
R01 · FY2003 · AI
FUNCTIONAL ROLE OF MBP 1$248,430
R01 · FY2003 · CA
FUNCTIONAL ROLE OF MBP 1$249,275
R01 · FY2002 · CA
HEPATITIS C VIRUS NS5A PROTEIN AND PATHOGENESIS$242,771
R01 · FY2002 · AI
FUNCTIONAL ROLE OF MBP 1$250,120
R01 · FY2001 · CA
HEPATITIS C VIRUS NS5A PROTEIN AND PATHOGENESIS$235,702
R01 · FY2001 · AI
HEPATITIS C VIRUS NS5A PROTEIN AND PATHOGENESIS$238,589
R01 · FY2000 · AI
C MYC PROMOTER BINDING PROTEIN$212,814
R01 · FY2000 · CA